Accepted Manuscripts                   Back to the articles list | Back to browse issues page

XML Print


Abstract:   (464 Views)
Aims: Intestinal colitis or ulcerative colitis is an inflammatory bowel disease that causes long-term inflammation and ulcers in the gastrointestinal tract. It has been suggested that mucosal expression of angiotensin II (AT-II) is increased in colitis. Here, we examined the potential therapeutic effects of combination therapy regarding Enalapril, as an Angiotensin-converting enzyme inhibitor, with sulfasalazine (SSZ) in a murine colitis model.
Methods: Male C57BL/6 mice divided to five groups: control group (distilled water), dextran sulphate sodium (DSS) (colitis group) (1 % DSS), SSZ (positive control group) with 100 mg/ kg/day, Enalapril alone group with 4 mg/kg/day, Enalapril (4 mg/kg/day) + SSZ (100 mg/kg/day).
Results: There was a significant reduction in disease activity index among the group of mice receiving the combination of Enalapril and SSZ compared to the colitis group. Enalapril and SSZ treatment was associated with a lower reduction in colon length, decreased colon weight, spleen weight and spleen-to-body weight in mice with colitis. Following DSS administration, Enalapril and SSZ also significantly decreased MDA levels as an oxidant marker, and increased total thiol, SOD, and CAT levels, as anti-oxidants. In addition, mucosal damage, crypt loss, pathological changes, and inflammation score decreased after treatment with Enalapril and SSZ in comparison with colitis group. The combination of Enalapril and SSZ reduced colon collagen content and caused fibrosis to decrease in comparison with colitis group.
Conclusion: The results of this study indicated that Enalapril alone and in combination with SSZ decreased inflammation and clinical symptoms of colitis induced by DSS.
     

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.